12.00MMarket Cap-161P/E (TTM)
0.525High0.500Low22.30KVolume0.510Open0.505Pre Close11.41KTurnover0.16%Turnover RatioLossP/E (Static)23.13MShares5.75052wk High0.27P/B7.31MFloat Cap0.43952wk Low--Dividend TTM14.09MShs Float13.200Historical High--Div YieldTTM4.95%Amplitude0.439Historical Low0.511Avg Price1Lot Size
Turnstone Biologics Stock Forum
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics (NASDAQ: TSBX)presented preclinical data on their Selected TIL technology at the 2024 SITC Annual Meeting. The research focuses on selectively expanding tumor-reactive T cells for solid tumor treatment. Two key studies were presented...
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, with a 25% overall response rate and 50% disease control rate.
2. Cash position of $62.4 million, expected to fund operations into Q...
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Turnstone Biologics Corp. (Nasdaq: TSBX) reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (MSS mCRC). Key findings include:
- 25% overall response rate (ORR) and 50% disease control rate (DCR) among four evaluable patients
- One patient achieved a deep and durable o...
Larger Image: tradingview.com...
$Turnstone Biologics (TSBX.US)$
Larger Image: tradingview.com...
$Turnstone Biologics (TSBX.US)$
Larger Image: tradingview.com...
$Turnstone Biologics (TSBX.US)$
Larger Image: tradingview.com...
$Turnstone Biologics (TSBX.US)$
No comment yet